The Agricultural Clean Technology (ACT) Program is a $25-million, three-year investment (2018 – 2021) which aims to support research, development and adoption of clean technologies through investments in, and promotion of precision agriculture and agri-based bioproducts. These technologies will help to reduce greenhouse gas emissions, generate a wide range of positive impacts, and promote sustainable and clean growth.

Support is available in the form of non-repayable contributions from Agriculture and Agri-Food Canada.

There is currently a high demand for funding under the Agricultural Clean Technology (ACT) Program, and funding is now very limited for the final year of the Program (April 1, 2020 to March 31, 2021). Applications must be received and deemed complete by the Program before September 30, 2020. Please contact the Program’s administration at aafc.actprogram-programmetpa.aac@canada.ca prior to submitting an application to the Program for funding.

The call for applications to the 2021 CIFAR Azrieli Global Scholars program is now open. We invite you to share this opportunity with outstanding early-career faculty in your networks, from all over the world.

The CIFAR Azrieli Global Scholars program supports exceptional early-career researchers with funding, mentorship, a global network, and professional skills development.

Please contact Jill Sherman, International Research Facilitator at intl.research@lakeheadu.ca if you are interested in applying to this opportunity.

 - Dream of a Cure, CHS Research Program

                   - Summer 2021 Dream of a Cure Studentships in Inherited Bleeding Disorders Research

                   - CHS/Pfizer Care Until Cure Research Program

                      - CHS/Novo Nordisk Psychosocial Research Programme

                                - CHS – Bayer – ADVANCE Canada Research Program

Dear Madam/Sir,

The Canadian Hemophilia Society (CHS) is proud to put out its call for applications for its research programs for the 2021-2022 grant period. The deadline to submit applications for all the programs is November 16, 2020. The eligibility criteria and conditions for all our research programs have been revised and updated. Of note, eligibility has been expanded as follows:

Ø  Dream of a Cure: the program is no longer limited to hemophilia A & B-related projects so that projects focusing on von Willebrand disease, rare factor deficiencies, platelet function disorders (and platelet pathophysiology) and other congenital and acquired bleeding disorders can be supported;

Ø  Dream of a Cure Studentships in Inherited Bleeding Disorders Research: similarly to our basic scientific research program, the studentships are no longer limited to hemophilia-related projects but include all inherited bleeding disorders. Furthermore, science students in any year of an undergraduate program can apply in addition to medical students in any year of training;

Ø  CHS/Pfizer Care Until Cure Research Program: the areas of interest to which investigators are encouraged to submit proposals has been expanded to include mild hemophilia A and B and Factor Utilization & Cost-effectiveness; all projects included but not limited to the list will be considered;

Ø  CHS/Novo Nordisk Psychosocial Research Programme: applications from Social Workers, Nurses, or Physiotherapists with professional experience in a hemophilia treatment centre (or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders) or persons interested in the field of inherited bleeding disorders will be considered. Students in a PhD program in one of the allied health disciplines may also apply. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. Professional experience in a hemophilia treatment centre is desirable but not required.

Ø  CHS/Bayer ADVANCE Canada Research Program:  applicant must be a physician or Ph.D. with professional experience in a hemophilia treatment centre (HTC) or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. The proposed research must have relevance to current practice in bleeding disorders care and may incorporate a broad spectrum of quantitative and qualitative research methods addressing professional practice with individuals, families, groups and communities, organizational issues, public health, and education.The research studies should aim to provide better data and tools to help the treaters assist patients in successful ageing.

DREAM OF A CURE

Through funds provided by the Hemophilia Research Million Dollar Club and the CHS, the CHS provides basic scientific research grants and studentships aimed at developing treatments for hemophilia A and B, von Willebrand disease, rare factor deficiencies, platelet function disorders and ultimately, finding a cure.

Dream of a Cure, the CHS Research Program and the 2021 Dream of a Cure Summer Studentships in Inherited Bleeding Disorders Research application forms as well as the general criteria and conditions are available by accessing the CHS Web site at https://www.hemophilia.ca/chs-dream-of-a-cure-research-program/. For Dream of a Cure, individual grants will be awarded to researchers for one to two years for amounts up to $75,000 per year while support will be offered to interested Canadian medical or science students for up to 4 months for a maximum stipend of $6,000 per student. 

______________________________

CHS / PFIZER CARE UNTIL CURE RESEARCH PROGRAM

You will find at https://www.hemophilia.ca/the-chspfizer-care-until-cure-research-program/ the information for the CHS/Pfizer Care until Cure Research Program offered by the CHS in collaboration with Pfizer Canada. This program allows Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders. Grants for one to two years with a maximum of $75,000 per year will be awarded for clinical research, including outcome evaluation, in fields relevant to improving the health and the quality of life for persons with Hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C infection, and carriers of an inherited bleeding disorder.

 
______________________________

CHS/NOVO NORDISK CANADA PSYCHOSOCIAL RESEARCH PROGRAMME

The CHS/Novo Nordisk Canada Psychosocial Research Program was created to engage hemophilia program professionals/graduate students from the allied health disciplines (ie. Nursing, Physiotherapy & Social Work) in research activities addressed to understanding the psychosocial impact of hemophilia and other inherited bleeding disorders and to improve the quality of life of persons and families whose lives are affected by these disorders.

The primary intent of this program is to offer one or two $20,000 research grants, to a maximum of $40,000 for one year.

Depending upon the number and quality of applications, funding for more than two research grant could be offered within the allotted total budget stated above.

The major portion of each grant would be to cover the research time for the successful candidate(s), including the time for research assistants. A small amount can be devoted to project expenses.

Multidisciplinary Collaboration:
Collaboration with multidisciplinary care providers and/or between two or more hemophilia centres is accepted and encouraged. Collaboration efforts may include, for example, social work, physical therapy and genetics. It thus may be possible for a hemophilia centre team to jointly submit a cooperative research project. Additionally, inter-regional applications will be considered.
 
Applications and Deadline:
A letter of intent should be submitted to the Canadian Hemophilia Society by November 16, 2020. The letter, with a maximum of two pages, should identify the researcher, the organization and include a summary description of the intended area of research.

The CHS Peer Review Committee will invite a limited number of candidates to submit a more detailed proposal by January 18, 2021 in order to make a final selection. Grants will be offered for a one-year period to begin in April 2021.

More detailed information is available by accessing the CHS Web site at https://www.hemophilia.ca/the-chsnovo-nordisk-psychosocial-research-program/

______________________________

The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program

The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population.

The research program will support studies that aim to:

•             Identify and provide insight into key issues associated with the ageing hemophilia population

•             Identify how management of age-related co-morbidities should be adapted to those with hemophilia

•             Create and deliver evidence-based information to health care practitioners (HCPs), the public and policy makers that will lead to improved care and QoL for older Canadians living with hemophilia

The primary intent of this program is to offer one or two $30,000 research grants, to a maximum of $60,000 for one year.

Applications and Deadline:
All completed application forms and support documents must arrive at the National Office of the Canadian Hemophilia Society on or before November 16, 2020.

Additional information, the eligibility criteria and conditions for the research program as well as the application form can be found on our website at this link:

https://www.hemophilia.ca/research-chs-bayer-advance-canada-research-program/

______________________________

Please feel free to distribute this information to others who may be interested in applying. The research must be conducted in Canada by researchers affiliated with Canadian universities and not-for-profit-related organizations.

If you require further information, please do not hesitate to contact Mr. Michel Long at the CHS National Office at 1-800-668-2686 or by e-mail at mlong@hemophilia.ca.

Sincerely,

Michel Long
National Program Manager | Gestionnaire national des programmes
Canadian Hemophilia Society | Société canadienne de l'hémophilie

301-666, rue Sherbrooke Ouest, Montréal (QC) H3A 1E7
'  514 848-0503, # 225 | 1 800 668-2686

   514 848-9661

   mlong@hemophilia.ca 
www.hemophilia.ca

Conference and Workshop Grants are for amounts up to $20,000. In accordance with the mission of the Foundation, priority is given to events that foster the creation of an international community of research scholars in anthropology and advance significant and innovative anthropological research.

Conferences are defined as public events that are comprised primarily of oral and poster presentations to a larger audience of anthropologists. Priority is given to major conferences sponsored by large international anthropological organizations (e.g., the European Association of Social Anthropologists, European Anthropological Association, Pan African Anthropological Association, and Latin American Anthropological Association) that serve as their annual or periodic meetings. The majority of the funds granted to such conferences is expected to be used towards expenses for international scholars who are making presentations at the conference and would not otherwise be able to attend.

Workshops are defined as working meetings that focus on developing and debating topical issues in theoretical anthropology. Workshops involve a small group of scholars who meet for a sufficient period of time to deal intensively with the topic. Priority is given to those workshops that devote the majority of time to discussion and debate rather than to the presentation of papers. It is expected that workshops will result in a publication.

Thanks to the generous financial support from the International Development Research Centre, up to $3 million CAD will be allocated via the expansion of the QES Advanced Scholars program, which will support doctoral researchers, post-doctoral fellows and early career researchers from eligible West African countries and Canada.

This call will support projects contributing to advance the UN’s Sustainable Development Goals (SDGs), with preference given to proposals that focus on or clearly integrate SDG 5 (gender equality) as a crosscutting or mainstream goal. QES-AS West Africa projects will focus on one or more of the following areas: climate resilience and sustainable food systems; education and innovation systems; ethics in development research; health equity; inclusive governance; and sustainable inclusive growth.

The program will require all scholars to participate in leadership development and community engagement activities and in the network of Queen Elizabeth Scholars.

Description

The Postdoctoral Fellowships (PDF) program provides support to a core of the most promising researchers at a pivotal time in their careers. The fellowships are also intended to secure a supply of highly qualified Canadians with leading-edge scientific and research skills for Canadian industry, government and academic institutions.

Eligibility

To be considered eligible for support, as of the deadline date of the year in which you apply, you must

• be a Canadian citizen or a permanent resident of Canada
• hold or expect to hold a doctorate in one of the fields of research that NSERC supports

ROSES-2020 Program Element A.5 Carbon Cycle Science solicits proposals for research focused on carbon stocks and fluxes between and within freshwater, marine systems, and land ecosystems, and their exchange with the atmosphere. It also targets improving understanding of carbon cycle processes and feedbacks in critical ecosystems that are particularly vulnerable to environmental change. Substantive use of remote sensing and/or airborne data is required in all studies.

The research topics of interest for this program element are divided into two sub-elements, which are further divided into five research topics:

3.1: Carbon Fluxes between and within Land, Freshwater, and Marine Systems

3.1.1.    The Land-Ocean Continuum

3.1.2.    Carbon Cycle of Critical Ecosystems: Vulnerability of Tropical Forests

3.1.3.    Fluxes and Biogeochemistry of Carbon within Oceans

3.2: Carbon Fluxes between Ecosystems and the Atmosphere

3.2.1.    Carbon Fluxes between Terrestrial Ecosystems and the Atmosphere

3.2.2.    Carbon Fluxes between Oceans and the Atmosphere

ROSES-2020 Amendment 49 releases final text for A.5 Carbon Cycle Science. Notices of intent are requested by September 28, 2020 and the due date for proposals is December 3, 2020.

On or about August 26, 2020, this Amendment to the NASA Research Announcement "Research Opportunities in Space and Earth Sciences (ROSES) 2020" (NNH20ZDA001N) will be posted on the NASA research opportunity homepage at http://solicitation.nasaprs.com/ROSES2020 and will appear on SARA's ROSES blog at: https://science.nasa.gov/researchers/sara/grant-solicitations/roses-2020/.

Questions concerning A.5 Carbon Cycle Science may be directed to Laura Lorenzoni, who may be reached at  Laura.Lorenzoni@nasa.gov.

The FY20 Defense Appropriations Act provides funding to the Department of Defense Rare Cancers Research Program (RCRP) to support for research of exceptional scientific merit in the area of rare cancers research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY20 RCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Vision Statement

To greatly improve outcomes for people with rare cancer through discovery and community building, and expansion of knowledge across the cancer landscape

Mission Statement

Elevate rare cancers research to enable clinically impactful discoveries for the benefit of Service members, their families, Veterans, and the American public

Applications for the Concept Award submitted to the FY20 RCRP must address one or more of the following Focus Areas:

• Biology and Etiology: Identify disease-defining molecular pathways, cell context, and microenvironment.
• Research Model: Develop and validate rare tumor-specific models that can support clinical trial readiness.
• Platform Development: Development of platforms (such as, tumor tissue repository with clinical annotation; centralized databanks; patient registry with common data structure; research model and Omics database; longitudinal studies of natural history and treatment response), for multiple rare cancers, to allow sharing data, bio-specimens and resources.
• Therapy: Identify novel therapeutic strategies, including drug repurposing.

Applications for the Idea Development Award submitted to the FY20 RCRP must address one or more of the following Focus Areas:

• Biology and Etiology: Identify disease-defining molecular pathways, cell context, and microenvironment.
• Research Model: Develop and validate rare tumor-specific models that can support clinical trial readiness.
• Therapy: Identify novel therapeutic strategies, including drug repurposing.

Applications for the Resource and Community Development Award submitted to the FY20 RCRP must address the Focus Areas below:

• Platform Development: Development of platforms (such as, tumor tissue repository with clinical annotation; centralized databanks; patient registry with common data structure; research model and Omics database; longitudinal studies of natural history and treatment response), for multiple rare cancers, to allow sharing data, bio-specimens and resources.

https://cdmrp.army.mil/funding/rcrp

Concept Award – Letter of Intent due November 12, 2020

Investigators at or above the level of postdoctoral fellow

• Supports innovative, high-risk/high-reward research that is in the earliest stages of idea development or an untested theory that addresses an important problem related to rare cancers.  Proof-of-concept is the anticipated outcome.
  • Submission should address at least one of the FY20 Focus Areas.
  • Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s).
    • Preliminary data are not required.
    • Clinical trials are not allowed.
    • Maximum funding of $100,000 for direct costs (plus indirect costs) 
    • Maximum period of performance is 1 year

Idea Development Award – Letter of Intent due November 12, 2020

Investigators at or above the level of Assistant Professor

• Supports innovative, high-risk/high-reward research with the potential to yield impactful data in the rare cancer field.
• Preliminary data with disease specific rationale (including correlatives in existing trials) to support the feasibility of the research hypotheses and research approaches are required.
• Submission should address at least one of the FY20 Focus Areas.
• Clinical trials are not allowed.
• Maximum funding of $350,000 for direct costs (plus indirect costs)  
• Maximum period of performance is 3 years

Resource and Community Development Award – Letter of Intent due November 12, 2020

Investigators at or above the level of Assistant Professor

• Emphasis on research resources development and information sharing among stakeholders, such as researchers, caregivers, clinicians, and other members of the rare cancers community.
• Supports platform development or infrastructure that can be applied to multiple rare cancers.
• Submission should address the Platform Development Focus Area.
• Preliminary data are not required but may be included (Translational research and clinical studies may be included).
• Clinical trials are not allowed.
• Maximum funding of $600,000 for direct costs (plus indirect costs) 
• Maximum period of performance is 3 years

A Letter of Intent (LOI) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the LOI deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the RCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org